Johnson & Johnson (FRA:JNJ)
136.54
-1.26 (-0.91%)
Last updated: Apr 23, 2025
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B USD in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
3.99
Revenue / Employee
$646.86K
Employees
138,100
Market Cap
328.88B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 34.18B |
Deutsche Telekom AG | 118.43B |
Siemens Aktiengesellschaft | 76.54B |
Allianz SE | 107.35B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.15B |
Rheinmetall AG | 9.75B |
Merck KGaA | 21.16B |
Siemens Energy AG | 35.76B |
Johnson & Johnson News
- 1 day ago - 2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market - Seeking Alpha
- 2 days ago - Two Stocks To Consider During Market Unrest To Provide Income Stability - Seeking Alpha
- 3 days ago - JNJ says new data buoys TAR-200 monotherapy for bladder cancer - Seeking Alpha
- 3 days ago - Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know - Benzinga
- 3 days ago - Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA - PRNewsWire
- 3 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 4 days ago - IBM, Parker-Hannifin Among 10 Companies To Announce Dividend Increases In Second Half Of April - Seeking Alpha
- 4 days ago - Johnson & Johnson (JNJ) Sees Growth Amid Trade Tensions - GuruFocus